Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameVincent Med
Stock Code01612
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為OEM客戶製造各種醫療器械(主要為呼吸產品、造影劑壓力注射器一次性產品以及骨科支護具康復器具),並以自有品牌「英仕醫療」開發、製造及銷售呼吸設備、一次性產品以及骨科支護具康復器具。
Listing Date2016-07-13
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港九龍紅磡德豐街22號海濱廣場2座16樓1604-07A室
Business Address (Hong Kong)香港紅磡鶴園街2G號恆豐工業大廈2期7樓B2室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitevincentmedical.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.00 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.01 / shares
Offer Period2016-06-30 to 2016-07-06
Global Offering Shares127,600,000 shares
HK Public Offer Shares (Initial)12,760,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)114,840,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO638,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 127,600,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 524M
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +1749%

Valuation & Financials

Market Cap (at Offer Price)HK$ 717,750,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約71.7百萬港元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 HKD
Income Statement
Item 201320142015
Profit for the year 27,01042,39671,656
Balance Sheet
Item 201320142015
Cash and cash equivalents 68,75461,86269,303
Trade and bills receivables 76,89089,22687,188
Inventories 39,92666,51865,422
Total current assets 200,912232,964238,575
Total assets 240,701296,385319,968
Total current liabilities 93,803127,68796,903
Total equity 146,898168,698217,087
Equity attributable to owners 120,271138,533169,358
Interest-bearing borrowings 1,8006004,717
Cash Flow Statement
Item 201320142015
Net cash from operating activities 41,25143,99754,551
Net cash from investing activities -9,551-29,302-15,569
Net cash from financing activities -20,654-21,201-25,204
Net increase in cash 11,046-6,50613,778
Depreciation of PP&E 10,82412,37013,216
Amortisation of intangible assets 0096
Purchase of PP&E -9,844-22,730-11,320
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 0.94
First Day OpenHK$ 0.99
First Day Change-6.00%
First Day Volume31090000.0
First Day Turnover29420600.0
Use of Proceeds
1、約50.0%或47.9百萬港元用于2016年至2018年擴充及升級生產設施; 2、約27.0%或25.8百萬港元用于2016年至2018年開發在研及計劃中產品; 3、約18.0%或17.2百萬港元,用于2016年至2018年銷售及營銷; 4、約5.0%或4.8百萬港元,用于一般公司用途及營運資金。

Underwriting Syndicate

Sole Sponsor (1)
BOSC International Company Limited CE BDP643
Overall Coordinators (1)
BOSC International Company Limited CE BDP643
Joint Bookrunners (3)
BOSC International Company Limited CE BDP643 Crosby Securities Limited CE BAP681 SHENWAN HONGYUAN CAPITAL (H.K.) LIMITED CE ABC209
Joint Lead Managers (5)
BOSC International Company Limited CE BDP643 CGS International Securities Hong Kong Limited CE AAW351 Crosby Securities Limited CE BAP681 HALCYON SECURITIES LIMITED CE BAM857 SHENWAN HONGYUAN CAPITAL (H.K.) LIMITED CE ABC209

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman蔡文成—
Company Secretary徐麗琪—
No director data available.

Major Shareholders

Major Shareholders & HoldingsVRI持有59.87%;蔡先生及廖女士被視為透過VRI持有59.87%;IGF持有9.60%;珠海華發集團有限公司及陳友正先生被視為透過IGF持有9.60%。
About this page

This page shows Vincent Med (01612) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect